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1208Objectives: Ex vivo lung perfusion (EVLP) is a promising modality for the evaluation and treatment of marginal
donor lungs. The optimal timing of EVLP initiation and the potential for rehabilitation of donor lungs with ex-
tended warm ischemic times is unknown. The present study compared the efficacy of different treatment strat-
egies for uncontrolled non–heart-beating donor lungs.
Methods: Mature swine underwent hypoxic arrest, followed by 60 minutes of no-touch warm ischemia. The
lungs were harvested and flushed with 4C Perfadex. Three groups (n ¼ 5/group) were stratified according to
the preservation method: cold static preservation (CSP; 4 hours of 4C storage), immediate EVLP (I-EVLP:
4 hours EVLP at 37C), and delayed EVLP (D-EVLP; 4 hours of CSP followed by 4 hours of EVLP). The
EVLP groups were perfused with Steen solution supplemented with heparin, methylprednisolone, cefazolin,
and an adenosine 2A receptor agonist. The lungs then underwent allotransplantation and 4 hours of recipient
reperfusion before allograft assessment for resultant ischemia–reperfusion injury.
Results: The donor blood oxygenation (partial pressure of oxygen/fraction of inspired oxygen ratio) before
death was not different between the groups. The oxygenation after transplantation was significantly greater in
the D-EVLP group than in the I-EVLP or CSP groups. The mean airway pressure, pulmonary artery pressure,
and expression of interleukin-8, interleukin-1b, and tumor necrosis factor-awere all significantly reduced in the
D-EVLP group. Post-transplant oxygenation exceeded the acceptable clinical levels only in the D-EVLP group.
Conclusions: Uncontrolled non–heart-beating donor lungs with extended warm ischemia can be reconditioned
for successful transplantation. The combination of CSP and EVLP in the D-EVLP group was necessary to obtain
optimal post-transplant function. This finding, if confirmed clinically, will allow expanded use of nonheart-
beating donor lungs. (J Thorac Cardiovasc Surg 2012;144:1208-16)Lung transplantation is a lifesaving treatment for patients
with end-stage pulmonary disease; however, its success is
limited by significant donor organ shortages. To address
this growing problem, many centers now use a limited
number of marginal or extended-criteria heart-beating
(HB) donor lungs. Recently, the transplantation of lungs
from non–heart-beating (NHB) donors has gained renewed
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The Journal of Thoracic and Cardiovascular Surshortages. NHB donors are classified by Maastricht cate-
gory according to the circumstances of expiration (I, dead
on arrival to the hospital; II, failed resuscitation; III, with-
drawal of life support, awaiting cardiac arrest; and IV,
cardiac arrest in a brain-dead donor), and further described
as uncontrolled (categories I and II) and controlled (cate-
gories III and IV) donors.1 However, several case series us-
ing NHB donor lungs for transplantation have shown
greater rates of primary graft dysfunction, bronchiolitis ob-
literans, and mortality compared with HB donor lungs.
Also, accurately predicting the post-transplantation
function of NHB donors lungs has proved difficult, in part
because of the variations in warm ischemic times.2-4
Ex vivo lung perfusion (EVLP) is a technique of normo-
thermic acellular lung perfusion for both donor lung assess-
ment and rehabilitation ex vivo.5,6 The promise of this
technique has been demonstrated in recent human clinical
trials of marginal donor lungs (Maastricht categories III
and IV). However, questions remain regarding the optimal
timing of EVLP, the potential application as a platform
for therapeutic delivery, and the rehabilitation potential
for Maastricht category I and II donor lungs.7,8gery c November 2012
Abbreviations and Acronyms
A2AR ¼ adenosine 2A receptor
BAL ¼ bronchoalveolar lavage
CSP ¼ cold static preservation
D-EVLP ¼ delayed ex vivo lung perfusion
EVLP ¼ ex vivo lung perfusion
HB ¼ heart-beating
I-EVLP ¼ immediate EVLP
IL ¼ interleukin
NHB ¼ non–heart-beating
PA ¼ pulmonary artery
TNF-a ¼ tumor necrosis factor-a
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XThe purpose of the present study was to determine, using
a preclinical porcine transplant model, whether lungs from
uncontrolled NHB donors (Maastricht category I) with ex-
tended warm ischemic times could be rehabilitated to an ac-
ceptable functional status for subsequent successful
transplantation. We hypothesized that initiation of EVLP
immediately after NHB donor lung explantation would
minimize the cold ischemic time, allow for rapid initiation
of directed donor lung treatment, and result in superior out-
comes after lung transplantation compared with either cold
static preservation (CSP) alone or delayed initiation of
EVLP (D-EVLP) after a period of CSP.
MATERIALS AND METHODS
Animals
The University of Virginia’s institutional animal care and use committee
reviewed and approved all aspects of the present study. Humane animal care
was observed, in accordancewith the ‘‘Guide for Care and Use of Laboratory
Animals’’ (National Institutes of Health, publication no. 85-23, revised 1985).
Study Groups
Mature domestic swine of both genders (weight, 20-38 kg) were ran-
domized throughout the study to 3 different study groups (n ¼ 5/group)
stratified according to donor lung preservation method. The donor swine
for all groups underwent hypoxic arrest, followed by 60 minutes of no-
touch warm ischemia. The CSP group underwent lung procurement and
4 hours of storage in 4C Perfadex (Vitrolife Inc, Denver, CO),
a commercially available preservative solution widely used for human
lung transplantation. The left donor lungs were subsequently transplanted
into size-matched recipients. The CSP group served as the ischemia–reper-
fusion injury control group. The immediate EVLP (I-EVLP) group under-
went lung procurement and 4 hours of immediate normothermic EVLP,
followed by transplantation. The D-EVLP group received a combination
of both strategies and underwent lung procurement, 4 hours of CSP in
4C Perfadex, followed by 4 hours of normothermic EVLP before trans-
plantation. After left lung transplantation, the lungs of all swine were per-
fused in vivo for a continuous 4-hour period, after which the parameters of
lung function and injury were assessed as described in the next sections.
Porcine Arrest and Donor Lung Procedure
The donor swine were anesthetized with ketamine (50 mg/kg) and xy-
lazine (5 mg/kg), ventilated with room air, and intubated. After intubation,
anesthesia was maintained for 10 minutes with 3% isoflurane, and theThe Journal of Thoracic and Carlungs were ventilated with 100% fraction of inspired oxygen using a vol-
ume control ventilator (Harvard Apparatus, Boston,Mass) at a tidal volume
of 8 mL/kg, respiratory rate of 14 to 18 breaths/min, and a positive end-
expiratory pressure of 5.0 cm H2O. Each pig was placed in the supine po-
sition, and continuous electrocardiographic monitoring was initiated. After
10 minutes, a baseline arterial blood gas sample was obtained by percuta-
neous withdrawal from the carotid artery. After arterial blood gas measure-
ment, the ventilator was disconnected, the endotracheal tube was occluded,
and the pig was euthanized by hypoxic arrest. The electrocardiographic
activity was monitored until full cessation of electric activity occurred, at
which point the pig was declared dead. After death, the pig was kept at
room temperature for a 60-minute no-touch period. Ventilation was then re-
sumed with pre-euthanasia settings, and lung harvesting was performed
using a standard operative technique, as previously described.9
In brief, the donor pigs underwent a median sternotomy and pericardiot-
omy to expose the heart, great vessels, and both lungs. Themain pulmonary
artery (PA) was cannulated with a cardioplegia cannula (Sarns, Ann Arbor,
Mich), the PAwas crossclamped proximal to this point, and prostaglandin
E1 (10 mg/kg) was injected directly into the main PA. The left atrial ap-
pendage was incised, the superior and inferior vena cavae were ligated,
and antegrade flushing of both lungs was performed with 1.5 L of 4C Per-
fadex. Because of the prolonged warm ischemic time, clot formation was
commonly encountered in the left atrium and pulmonary veins. Heparin
(10,000 IU) was added to the Perfadex flush for all pigs. During the flush,
the left atrium was incised, and efforts were made to manually remove as
much clot as possible from the atrium and pulmonary veins (Figure 1, A).
On completion of the antegrade flush, both lungs were inflated with 100%
fraction of inspired oxygen to tidal volume, and the heart and both lungs
were explanted en bloc. The heart was then removed with care to preserve
a generous atrial cuff, and the lungs were retrograde flushed with an addi-
tional 500 mL of 4C Perfadex to remove any remaining clot from the pul-
monary vasculature. For the CSP and D-EVLP groups, the lungs were
placed in a standard preservation bag and stored in 4C Perfadex. For the
I-EVLP group, the lungs were placed directly in ex vivo perfusion.Porcine EVLP
EVLP was performed, as described previously10 and according to ear-
lier studies by Cypel and colleagues.6 In brief, a funnel-shaped plastic can-
nula (Vitrolife) was sewn to the left atrial cuff, a plastic cannula (Vitrolife)
was secured into the main PA, and an 8-0 endotracheal tube with the bal-
loon removed was secured into the trachea (Figure 1, B). The EVLP circuit
consisted of a bypass centrifugal pump (Medicus, Minneapolis, Minn),
membrane oxygenator, heat exchanger, venous reservoir (Sorin Group, Ar-
vada, Colo), and polyethylene tubing. The lungs were transferred to an
XVIVO chamber (Vitrolife), and retrograde flow was initiated through
the left atrium to de-air the pulmonary vasculature and flush any remaining
clot. The PA cannula was then connected, and antegrade flow was begun at
0.1 L/min. EVLP was performed using acellular Steen solution (Vitrolife),
a commercially available preservative solution designed for ex vivo lung
assessment, supplemented with 10,000 IU heparin (APP Pharmaceuticals,
Schaumburg, Ill), 500 mg cefazolin (Apotex Corp, Weston, Fla), 500 mg
methylprednisolone (Pfizer, NewYork, NY), and 3.0 ng/kg/min continuous
infusion of ATL-1223 (Dogwood Pharmaceuticals, Charlottesville, Va),
a selective adenosine 2A receptor (A2AR) agonist. ATL-1223was included
to optimize the rehabilitative potential of EVLP, becausewe had previously
established the potent anti-inflammatory effects of A2AR agonist in lung
ischemia–reperfusion injury and the potential protective advantages af-
forded with EVLP-directed A2AR agonist treatment.10-14 The perfusate
was slowly warmed to 37C during a 30-minute period as the flow was ti-
trated up to the target of 40% of the estimated cardiac output (estimated
cardiac output, 100 mL/kg). When the perfusate reached 32C, ventilation
was initiated with room air at a tidal volume of 8 mL/kg, respiratory rate of
8 breaths/min, and positive end-expiratory pressure of 5.0 cm H2O. After
initiation of ventilation, a mixture of 6% oxygen, 8% carbon dioxide,diovascular Surgery c Volume 144, Number 5 1209
FIGURE 1. Non–heart-beating donor lung harvest and ex vivo lung perfusion (EVLP) procedures. A, Fresh clot removed from donor left atrium and pul-
monary veins during antegrade lung flush. B, Donor lungs during EVLP with pulmonary artery cannula, left atrial cannula, and endotracheal tube secured in
place.
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oxygenate the PA perfusate and allow for accurate measurement of lung
oxygenation capability. At 1 and 4 hours after EVLP initiation, the lungs
were ventilated with 100% fraction of inspired oxygen for 10 minutes,
and a sample of the perfusate was taken from the left atrial return for
arterial blood gas analysis. At the conclusion of the 4-hour EVLP period,
the lungs were removed from the EVLP circuit, and an antegrade flush
was performed with 500 mL of 4C Perfadex. The lungs were separated,
the right lung was discarded, and the left lung was stored in 4C Perfadex
before transplantation.
Porcine Left Lung Recipient Transplantation
Transplantation of the left lung was performed as described previously.9
In brief, a left thoracotomy and left pneumonectomy were performed in
a size-matched recipient swine after heparin administration (5000 IU).
The donor lung was then brought into the field and the donor-to-recipient
left bronchus anastomosis was completed in continuous fashion, followed
by the donor-to-recipient pulmonary artery anastomosis. A portion of the
left atrial appendage was then isolated with a side-biting vascular clamp,
the atrium was incised, and the donor atrial cuff was anastomosed to the
recipient atrial appendage in continuous fashion. The vascular and airway
clamps were then removed to establish reperfusion and ventilation of the
transplanted lung.
Lung Physiologic Features
All transplanted lungs underwent 4 hours of in vivo reperfusion. During
reperfusion, hourly arterial blood gas measurements were obtained, in ad-
dition to the mean arterial pressure, heart rate, and mean PA pressure using
a Swan-Ganz catheter. Pulmonary function after transplantation was also
evaluated with mean airway pressure measurements obtained using a pres-
sure monitoring line attached to the endotracheal tube. After 3.5 hours, the
endotracheal tube was advanced into the left mainstem bronchus, and the
right main pulmonary artery was occluded by a preplaced vessel loop,
thereby establishing isolated perfusion and ventilation of the transplanted
left lung that continued for 30 minutes. On isolation, the ventilator settings
were changed to a tidal volume of 5 mL/kg (equivalent to approximately1210 The Journal of Thoracic and Cardiovascular Sur10 mL/kg on the isolated left lung), and the rate was increased to maintain
minute ventilation. On conclusion of the 30-minute isolated reperfusion pe-
riod, additional assessment of the recipient swine and the transplanted do-
nor lung was performed using final arterial blood gas, pulmonary function,
and PA catheter measurements before explantation of the transplanted lung.Cytokine Measurement
Bronchoalveolar lavage (BAL) of the upper lobe of the left lung was
performed immediately after explantation in all groups using 40 mL
normal saline. BAL samples were centrifuged at 1800 rpm for 8 minutes,
and the supernatant was then stored at80C. Quantification of cytokine
levels in the BAL fluid was assessed using a commercially available por-
cine cytokine multiplex immunoassay kit (RayBiotech, Norcross, Ga).Histopathologic Findings and Lung Injury Severity
Score
The lower lobe was fixed in 10% buffered formalin using tracheal infla-
tion to 25 cm H2O. Three tissue specimens were obtained from standard-
ized locations within the lung parenchyma, with subsequent paraffin
embedding and hematoxylin-eosin staining. The lung sections were blindly
assessed by a lung pathologist and graded according to the total neutrophil
counts per high power field, extent of alveolar edema, and degree of inter-
stitial infiltration. A score on a scale of 0 to 3 was assigned for each section
using previously reported criteria9: neutrophils per high powered field
(score of 0,<5; 1, 6 to 10; 2, 11 to 20; and score of 3,>20), alveolar edema
(score of 0,<5%; 1, 6%-25%; 2, 26%-50%; and 3,>50%), and inter-
stitial infiltration (score of 0, none; 1, minimal; 2, moderate; and 3, severe).
A composite score was obtained by summation of these 3 criteria (total
score range, 0-9). The average of the 3 sample values for each variable
was obtained for group comparisons.Statistical Analysis
All experimental methods were designed to test the null hypothesis that
no significant differences in the degree of injury would be observed despitegery c November 2012
FIGURE 2. Lung physiology after 4 hours of reperfusion. A, Mean airway pressure. B, Mean pulmonary artery pressure. C, Oxygenation, represented by
partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio measured at 4 points: donor arterial blood oxygenation before death, ex vivo lung
perfusion (EVLP)-perfusate oxygenation at 1 hour, EVLP-perfusate oxygenation at 4 hours, and recipient arterial blood oxygenation at end of transplan-
tation. CSP, Cold static preservation; I-EVLP, immediate EVLP; and D-EVLP, delayed EVLP. A and B, *P<.05 versus CSP; #P<.05 versus CSP and
I-EVLP. C, *P<.05 versus I-EVLP; #P<.05 versus CSP and I-EVLP.
Mulloy et al Cardiothoracic Transplantationthe different preservation strategies. Independent, pairwise group compar-
isons were performed using the unpaired Student’s t-test. Experimental re-
sults are reported as the mean  standard deviation.T
XRESULTS
Lung Function
Although we hypothesized that the I-EVLP lungs would
function better after transplantation, instead we observed
that lung function was significantly improved in the
D-EVLP group compared with either CSP or I-EVLP
(Figure 2). Compared with the CSP group, the final blood
oxygenation was significantly greater in the D-EVLP group
(D-EVLP, 508.7  90.4; vs CSP, 159.4  70.1; P<.001),
and the mean PA pressure (D-EVLP, 22.4  5.9 mm Hg;
vs CSP, 30.2 2.8 mm Hg, P¼ .03) and mean airway pres-
sure (D-EVLP, 6.8 0.8mmHg; vsCSP, 11.8 1.0mmHg;
P<.001) were significantly reduced. The D-EVLP group
also demonstrated significantly greater blood oxygenation
(D-EVLP, 508.7  90.4; I-EVLP, 228.5  130.7; P<.01),
significantly lower mean airway pressure (D-EVLP, 6.8 
0.8 mm Hg; I-EVLP, 10.1  2.6 mm Hg; P ¼ .03), and re-
duced mean pulmonary artery pressure (D-EVLP, 22.4 
5.9 mm Hg; I-EVLP, 29.2  11.0 mm Hg; P ¼ .26)The Journal of Thoracic and Carcompared with the I-EVLP group. Blood oxygenation
(I-EVLP, 228.5  130.7; CSP, 159.4  70.1; P ¼ .33), pul-
monary artery pressure (I-EVLP, 29.2  11.0 mm Hg; CSP,
30.2  2.8 mm Hg; P ¼ .85), and mean airway pressure
(I-EVLP, 10.1  2.6 mm Hg; CSP, 11.8  1.0 mm Hg;
P ¼ .27) did not significantly differ between the CSP and
I-EVLP groups. No significant differences were observed
among all groups in age, weight, mean total anastomotic
time, mean arterial pressure, or heart rate (data not shown).
All groups had similar pre-euthanasia donor blood oxy-
genation levels. A divergence was, however, present there-
after as a function of the preservation strategy used
(Figure 2, C). In the CSP group, blood oxygenation de-
creased from 419.4  108.9 before death to 159.4  70.1
after transplantation. Similarly, the pre-euthanasia blood
oxygenation in the I-EVLP group was high (406.1 
120.0), and the perfusate oxygenation levels steadily de-
creased throughout the EVLP period to a final blood oxy-
genation level of 228.5  130.7 after transplantation.
Oxygenation in the D-EVLP group started high (358.2 
151.1) and improved after the period of CSP and 1 hour
of EVLP (450.3  95.0). The oxygenation levels in the
D-EVLP group continued to improve through the end ofdiovascular Surgery c Volume 144, Number 5 1211
FIGURE 3. Mean proinflammatory cytokine levels in bronchoalveolar
lavage fluid at end of 4 hours of reperfusion. CSP, Cold static preservation;
I-EVLP, immediate ex vivo lung perfusion; D-EVLP, delayed ex vivo lung
perfusion. *P<.05 versus CSP; #P<.05 versus CSP and I-EVLP.
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XEVLP (477.6 88.7) and reached a final blood oxygenation
level of 508.7  90.4 after transplantation.
Proinflammatory Cytokine Expression
The effect of the various preservation strategies on the ex-
pression of proinflammatory cytokines in BAL fluid was as-
sessed at the end of reperfusion (Figure 3). In parallel with
the lung function results, the D-EVLP group had signifi-
cantly decreased expression of interleukin (IL)-1b (D-
EVLP, 259.5  87.3 pg/mL; CSP, 851.1  262.8 pg/mL;
P ¼ .001), IL-8 (D-EVLP, 112.1  74.8 pg/mL; CSP,FIGURE 4. Representative histologic (Top, hematoxylin-eosin sections, 320)
Cold static preservation; I-EVLP, immediate ex vivo lung perfusion; D-EVLP, d
1212 The Journal of Thoracic and Cardiovascular Sur531.5  331.4 pg/mL; P ¼ .03), and tumor necrosis factor
(TNF)-a (D-EVLP, 233.2  84.9 pg/mL; CSP, 1050.2 
353.8 pg/mL; P¼ .001) compared with the CSP group. Ad-
ditionally, the D-EVLP group demonstrated significantly
decreased IL-1b (D-EVLP, 259.5  87.3 pg/mL; I-EVLP,
566.3  202.1 pg/mL; P ¼ .01), IL-8 (D-EVLP, 112.1 
74.8 pg/mL; I-EVLP, 248.4  96.3 pg/mL; P ¼ .04), and
TNF-a (D-EVLP, 233.2  84.9 pg/mL; I-EVLP, 568.1 
218.2 pg/mL; P ¼ .01) compared with the I-EVLP group.
The I-EVLP group had intermediate cytokine levels, with
significantly decreased expression of TNF-a (P¼ .03) com-
pared with the CSP group (Figure 3). IL-1b (P ¼ .09) and
IL-8 (P ¼ .10) also decreased, but the differences did not
reach statistical significance.Gross and Histologic Evidence of Lung Injury
Overall, the D-EVLP group had an improved histologic
and gross appearance (Figure 4), in addition to decreased
lung injury scores (Figure 5), compared with the CSP and
I-EVLPgroups. The individual parameters of the lung injury
severity score demonstrated less injury in the D-EVLP
group than in the CSP group, with significantly fewer neu-
trophils per high-powered field (D-EVLP, 1.6  0.7; CSP,
2.6  0.6; P ¼ .04; Figure 5). The D-EVLP group also
had decreased alveolar edema (D-EVLP, 0.1  0.2; CSP,
0.5  0.6; P ¼ .13) and less interstitial infiltrate (D-EVLP,
0.9 0.6;CSP, 1.7 1.0;P¼ .12) than theCSPgroup.How-
ever, these variables did not achieve statistical significance.
Additionally, the composite lung injury severity scores were
less for theD-EVLP group than for the CSP group (D-EVLP,
2.5 1.2; CSP, 4.8 2.0; P¼ .06). The D-EVLP group hadand gross (Bottom) appearance of lungs after 4 hours of reperfusion. CSP,
elayed ex vivo lung perfusion.
gery c November 2012
FIGURE 5. Mean lung injury severity scores stratified by histologic feature. See text for details of assigned scores. CSP, Cold static preservation; I-EVLP,
immediate ex vivo lung perfusion; D-EVLP, delayed ex vivo lung perfusion; PMN, polymorphonuclear leukocytes; HPF, high power field. *P<.05 versus
CSP; #P<.05 versus I-EVLP.
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eter. However, these achieved statistical significance only
for the grade of interstitial infiltrate (D-EVLP, 0.9  0.5;
I-EVLP, 1.7 0.4;P¼ .03). The I-EVLP group did not dem-
onstrate a statistically significant reduction in any lung
injury parameter compared with the CSP group.
DISCUSSION
The present study used a preclinical porcine lung trans-
plantation model to demonstrate that EVLP can rehabilitate
lungs from uncontrolled NHB donors (Maastricht category
I) with extended warm ischemic times to an acceptable
functional status for successful transplantation. The results
of the present study, regarding the timing and initiation of
EVLP and inclusion of a CSP period, were contrary to
our initial hypothesis. These results have demonstrated
that a combination of 4 hours of CSP followed by 4 hours
of normothermic EVLP is significantly more protective
than either 4 hours of CSP or 4 hours of immediate EVLP
alone. This conclusion was supported by the finding that
the D-EVLP group demonstrated significantly improved
lung physiology, decreased proinflammatory cytokine ex-
pression, decreased neutrophil infiltration, and conserved
lung histologic features despite a doubling of the preserva-
tion period. Although the I-EVLP group did demonstrate
decreased proinflammatory cytokine expression and a trend
toward improved lung physiology compared with the CSP
group, these differences were not significant, unlike those
observed with the D-EVLP group. Therefore, although
our hypothesis was incorrect, we are encouraged by the
finding that excellent post-transplantation lung functionThe Journal of Thoracic and Carcan be achieved with uncontrolled NHB donor lungs with
extended warm ischemic times through the use of delayed
normothermic EVLP. Additionally, we believe that our
study provides the foundation for additional research di-
rected toward the goal of expanding the limited human
donor pool through the use of uncontrolled NHB donation.
One aspect of the present study that warrants additional
discussion is the use of ATL-1223, a selective A2AR ago-
nist, in the perfusion circuit for both EVLP groups. Our lab-
oratory has extensive experience with the use of selective
A2AR agonists in animal models of transplantation.11-13
It is well-established that specific A2AR activation de-
creases the release of TNF-a and other proinflammatory cy-
tokines, downregulates adhesion molecules (P-selectin,
intercellular adhesion molecule-1, and vascular cell adhe-
sion molecule-1), and blocks neutrophil activation and infil-
tration.13,15,16 We have recently demonstrated in a HB
donor porcine transplant model that ATL-1223 attenuates
ischemia–reperfusion injury after transplantation.9 In addi-
tion, we have shown that administration of a selective
A2AR agonist in the EVLP circuit effectively decreases in-
flammation and improves lung function in a porcine EVLP
nontransplant model.10 The present study was designed to
evaluate the capability for rehabilitation of uncontrolled
NHB donor lungs using EVLP. Given the known benefits
of ATL-1223 treatment and the unknown level of lung dys-
function incurred by either the mechanism of donor death or
the subsequent 60-minute warm ischemic time, we included
ATL-1223 in the EVLP circuit for both groups to enhance
the probability of achieving or exceeding acceptable lung
function outcomes. We recognize that a limitation of thediovascular Surgery c Volume 144, Number 5 1213
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clusions on the role of ATL-1223, just as we were unable to
make any conclusions on the roles of other agents currently
used in standard EVLP protocols. Both the I-EVLP and
D-EVLP groups underwent identical exposure to ATL-
1223, and our results have demonstrated that D-EVLP is
superior to I-EVLP in the setting of uncontrolled NHB
donor lung transplantation.
Conventional wisdom in organ transplantation holds that
the cold ischemic time is damaging to donor organs, and
theUnitedNetwork forOrgan Sharing has divided theUnited
States into 11 geographic transplant regions with the goal
of minimizing the transportation times to limit the donor
organ preservation periods.17,18 We found that a period
of CSP before EVLP was beneficial in optimizing
organ function and minimizing inflammation despite
the prolonged preservation period this strategy used.
Although our technique included an extended preservation
period, the benefits of this period have been supported by
previously published data. In a 2011 human clinical EVLP
trial, lungs from marginal and NHB Maastricht category III
and IV donors underwent EVLP after a period of CSP. The
EVLP donor lungs yielded equivalent post-transplantation
outcomes compared with the standard nonmarginal donor
lungs, despite an average of 10.9 hours of total preservation
time (vs 6.2 hours for the nonmarginal lungs).8 Additionally,
in the first reported series investigating the use of EVLP in
transplantation for standard HB donors, donor lungs under-
went CSP followed by EVLP, with a total preservation time
averaging 17.4 hours, and excellent post-transplantation
lung function was achieved in all patients.19
The benefit of hypothermia is well-established in clinical
protocols for organ preservation and protection. Hypother-
mia is the current clinical standard for neuroprotection
during cardiac surgery and is an emerging treatment for
patients after cardiac arrest. The benefit of hypothermia
has been proposed to involve mechanisms beyond the
slowing of metabolism with colder temperatures.20,21
Multiple mechanisms for hypothermic protection have
been previously described and include decreased free
radical production,22 inhibition of apoptosis,23 suppression
of the inflammatory response by inhibition of neutrophil in-
filtration,24 reduction of lipid peroxidation and leukotriene
production,25 and attenuation of the nitric oxide response.26
Applying this knowledge to the present study, we propose
that establishment of lung hypothermia before the initiation
of EVLP serves to effectively arrest the ongoing tissue dam-
age and inflammatory response associatedwith the extended
warm ischemic time. Subsequent acellular EVLP with the
addition of anti-inflammatory compounds, including meth-
ylprednisolone and ATL-1223, provides a therapeutic envi-
ronment for tissue rehabilitation before transplantation. In
contrast, transplantation directly after CSP results in ampli-
fication of the ischemia–reperfusion inflammatory cascade,1214 The Journal of Thoracic and Cardiovascular Surwith subsequent donor organ injury. Similarly, we propose
that initiation of EVLP immediately at the conclusion of
the warm ischemic period results in a sustained, hostile
proinflammatory environment within the donor lung, ulti-
mately leading to additional organ damage. Additional
study of the cellular and molecular mechanisms behind
the observed results is required, because our study was lim-
ited by the absence of mechanistic data, both throughout the
preservation process and after graft reperfusion. Despite this
limitation, these data have demonstrated that functional pa-
rameters during the EVLP period provide predictive infor-
mation regarding the potential graft function and
candidacy for transplantation. With this understanding, the
results of the present study have demonstrated that the com-
bination of CSP followed by normothermic EVLP effec-
tively reduces the inflammatory response and tissue injury
associated with NHB donor lung transplantation.
The findings of the present study support future studies to
define the rehabilitative mechanisms and optimal timing of
both CSP and EVLP. In the present study, both the donor
organ harvest and the subsequent storage procedure were
consistent with current clinical HB donor protocols. In ad-
dition, 4 hours of CSP was chosen to approximate the aver-
age donor lung cold ischemic time. Therefore, with proper
approval and consent, transplant centers could adopt EVLP
as a strategy to further study the assessment and rehabilita-
tion of uncontrolled Maastricht category I and II NHB
donor lungs. In addition to further study, our findings
support the continued inclusion of CSP in clinical EVLP
rehabilitation protocols. As we embark on the clinical
adoption of EVLP, our findings provide promise for the
inclusion of uncontrolled NHB donors in future human clin-
ical trials of lung transplantation.CONCLUSIONS
Delayed ex vivo lung perfusion after a period of CSP is an
effective strategy for the rehabilitation of uncontrolled NHB
donor lungs for subsequent transplantation in a preclinical
porcine transplant model. Clinical adoption of this lung
preservation strategy could be easily applied to current or-
gan procurement protocols. If clinically correlated in human
NHB donor lungs, the findings of the present study will lead
to improved human lung transplantation by allowing the safe
transplantation of uncontrolled NHB donor lungs, signifi-
cantly decreasing the donor organ shortage and saving lives.
We wish to thank Tony Herring, Cindy Dodson, and Sheila
Hammond for their technical and surgical assistance.References
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Dr David P. Mason (Cleveland, Ohio). Dr Mulloy, congratula-
tions on an impressive experiment and presentation. It is obvious
you put a lot of thought into the study design, and I am certain
the execution took a great amount of patience, as well as technical
expertise. I do not have any criticisms, although I do have 3
questions.
My first question. You designed a model of Maastricht category
I non–heart-beating donation with a 1-hour period of no-touch
warm ischemic time. Most lung transplantation performed
throughout theworld and all of it in the United States is withMaas-
tricht category III donors, which have a much shorter no-touch
time. Could you explain why you chose this model when it seems
that even category III donors are underutilized?
My second question pertains to the use of systemic heparin. In
your model, you gave no systemic heparin to the donor, and at har-
vest you noted a large amount of clot that you made great efforts to
remove. I wonder what role microscopic thrombosis played in
your graft function? Did you note any microscopic thrombi on his-
topathologic examination after animal death?
My last question. Your finding that immediate EVLP performed
worse than delayed EVLP is surprising. You suggest that this is ex-
plained by the protective effect of hypothermia that is better
achieved in the delayed EVLP during the 4-hour waiting period
on ice. After flushing with cold Perfadex, did the immediate
EVLP group receive any time on ice?
Thank you very much, and an excellent presentation and study.
Dr Mulloy. Thank you Dr Mason, for your kind comments and
excellent questions. I will answer them in the order that you asked.
The first question regarding why we chose Maastricht category I
versus III. Based on the experience from the Toronto group, we
know thatMaastricht category III lungs can be successfully assessed
and rehabilitated for subsequent transplantation using EVLP. In
their human clinical trial published last year, the Toronto group
showed that recipients of category III lungs that were assessed by
EVLP had equivalent clinical outcomes to standard lung transplant
recipients. Thus, we really designed this study as a ‘‘proof of con-
cept’’ study to demonstrate that uncontrolled Maastricht category
I donors could also be rehabilitated for successful transplantation.
That is why we chose a relatively longer ischemic time of 60 min-
utes, basically with the idea that if we could recondition these lungs
with extended warm ischemic times for successful transplantation,
we would prove that a significant proportion of uncontrolled non–
heart-beating donor lungs could be reconditioned.
Second, although the Maastricht category III donors are surely
underused, just from a pure numbers standpoint, the use of cate-
gory I donors would go much further toward solving the donor or-
gan shortage. Several hundred thousand people each year die of
cardiac arrest, and if we could use even 1% of those lungs, it would
go a long way toward solving the donor organ shortage.
Regarding the second question about the lack of heparin dosing
and the presence of microscopic thrombi, it is a great question, be-
cause thrombosis definitely did play a role in our study. At lung ex-
plantation, we did note clot both in the left atrium and in the
pulmonary veins, and we made all efforts to remove that clot.
However, clearly we were not able to remove all the clot, and I
am sure there was additional clot in the capillaries and smaller
vessels that we were unable to even visualize. I asked ourdiovascular Surgery c Volume 144, Number 5 1215
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Xhistopathologist about the presence of thrombi, and he did not no-
tice any mature fibrin thrombi in any of our samples. That being
said, the EVLP-treated lungs had heparin added to the acellular
perfusate, and also our recipient pigs were heparinized during
the 4-hour reperfusion period. Thus, I think the heparin during
the EVLP perfusion and recipient reperfusion likely dissolved
any existing thrombi, and I suspect that if we looked at the lung
histopathologic features immediately at explantation, we would
see extensive microscopic thrombi.
In fact, probably 1 of the great benefits of EVLP is that during
the acellular perfusion period you can treat with heparin to dis-
solve any existing clot in these uncontrolled donors.
Finally, the last question about whether the immediate group re-
ceived any hypothermia, the short answer to that question is yes.
After lung explantation, all lungs were taken to the back table
and flushed retrogradewith additional Perfadex. For the immediate
EVLP group, we then sewed in the EVLP cannulas as quickly as
possible, but that did take an average of 22 minutes. During that
period, the lungs were immersed in cold Perfadex; however, for ex-
posure reasons, they were not completely immersed. Thus, it was
really 22 minutes of partial hypothermia. In this study, obviously,
those 22 minutes of partial hypothermia were not adequate. Were
the full 4 hours of hypothermia used in the D-EVLP group before
EVLP necessary? Probably not. It is probably some period in the
middle that is needed to achieve the observed beneficial hypother-
mic effect.
Dr Michael J. Weyant (Aurora, Colo). I thought your presen-
tation was excellent and your project is very interesting. I had
a couple of questions, and I realize that you will probably touch
on these in later papers. Regarding the adenosine agonist treat-
ment. I did not notice whether you had given any in your flush
in your control group and whether you think that this plays
a role in the successful outcome of the long-term EVLP group,
and second, whether you did any analysis looking at whether the
receptors were downregulated or not in your specimens. I am
sure that you are planning on doing these. I am just curious to
know.
Dr Mulloy. Thank you for that question. I am sure a lot of you
know that our group has a long history of investigation into the use
of adenosine agonists in lung ischemia–reperfusion injury.
We did add the adenosine 2A receptor agonist to the flush in all
groups, and both of the EVLP groups received adenosine 2A ago-
nist dosing during EVLP. Therefore, we did not have an untreated
control group that would allow us to make specific statements
about the role of the adenosine-2A agonist in this study. We re-
cently published a study showing that the adenosine 2A agonist
prevented the ischemia–reperfusion injury related to lung trans-
plantation.We have also published our experience using a selective
adenosine 2A agonist during EVLP in a nontransplant porcine
model and demonstrated lung protection during EVLP with aden-
osine 2A receptor agonist. So again, with the present study de-
signed mainly as a proof-of-concept study, we opted to add the1216 The Journal of Thoracic and Cardiovascular Suradenosine 2A agonist to all groups. Now that we have proved
the concept, we plan to perform additional studies in which we
will have appropriate controls to determine exactly what the role
of the adenosine 2A agonist is in this model. Finally, we did not
check receptor upregulation or downregulation in this study but
plan to do so in future studies.
Dr Todd Rosengart (Stony Brook, NY). Congratulations on
a great study, a great circumstance in which an unexpected result
raises more questions than you anticipated. I think the obvious
question is, have your results begat the additional experimental
group of immediate cold reperfusion with or without agonists?
Is this something you have contemplated or done already, and if
not, what would you expect to find with that?
DrMulloy.Wehave not discussed performing cold reperfusion.
I think 1 of the lessons learned in this study is that we obtained ex-
cellent lung function from the delayed EVLP group. Thus, perhaps
with the additional use of EVLP, the standard cold static preserva-
tion period is not as damaging as is generally thought and could
probably be extended a little bit longer in many circumstances.
In my mind, the future translation of these results would be to
transport donor lungs on ice, then place them on normothermic
EVLP at certain centers that specialize in lung assessment and re-
habilitation, and then send them back out on ice to individual hos-
pitals for subsequent transplantation. However, regarding the role
of cold perfusion, we have not discussed that because we believe
that hypothermia is important for suppression of the inflammatory
response but does not allow for true rehabilitation or appropriate
functional assessment.
Dr Fabio De Robertis (Harefield, United Kingdom). Thank
you. I enjoyed your presentation very much. Congratulations for
your study.
That you did not administer systemic heparin is actually match-
ing what happens in the clinical setting in the United Kingdom.We
cannot heparinize the donor who experienced cardiac death. In the
clinical setting, we use category III or IV donors. But did you add
any heparin in the flush? Did you add anything else in the flush?
Did you use prostaglandin? The second question is: did you do
any retrograde flush, as well as antegrade flush? Did you use any-
thing else in the flush? Did you use prostaglandin? How did you do
that?
My third question is: of the lungs that did not improve in func-
tion, did you x-ray them, and if you did, what were the findings?
Dr Mulloy. I will answer your last question first. We did not x-
ray the lungs because we do not at this time have x-ray capabilities
in our animal operating theater.
Regarding the use of heparin, we did add 10,000 IU of heparin
to the Perfadex flush and also performed a retrograde flush. We
also infused prostaglandin E1 into the pulmonary artery immedi-
ately before starting the flush. However, even with those maneu-
vers, there was still clot present. When we placed the lungs on
EVLP, we would see clots continue to come out of the lungs for
the first 15 to 30 minutes.gery c November 2012
